<DOC>
	<DOCNO>NCT02808403</DOCNO>
	<brief_summary>The purpose post-marketing survey obtain real-world information safety effectiveness evolocumab Japan .</brief_summary>
	<brief_title>Long Term Post Marketing Specified Drug Use Result Survey Evolocumab Japan</brief_title>
	<detailed_description>The objective study 1 ) determine incidence adverse event adverse drug reaction among patient receive evolocumab 2 year , 2 ) identify describe patient characteristic ( e.g . demographic , medical history ) associate safety effectiveness evolocumab therapy patient Familial Hypercholesterolemia ( Heterozygous Homozygous ) Hypercholesterolemia Japan</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Patients evolocumab prescribed participate medical institution accordance approve Japan prescribe information ( i.e. , Familial Hypercholesterolemia ( Heterozygous Homozygous Hypercholesterolemia high risk factor cardiovascular event respond sufficiently HMGCoA reductase inhibitor ( statin ) hypercholesterolemia ) . No exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>